Vandetanib, Designed to Inhibit VEGFR2 and EGFR Signaling, Had No Clinical Activity as Monotherapy for Recurrent Ovarian Cancer and No Detectable Modulation of VEGFR2
Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-09-2308
Full Text
Open PDFAbstract
Available in full text
Date
January 12, 2010
Authors
Publisher
American Association for Cancer Research (AACR)